A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

被引：22

作者：

Watts, Justin M. ^{[1
]}

Bradley, Terrence J. ^{[1
]}

Thomassen, Amber ^{[2
]}

Brunner, Andrew M. ^{[3
]}

Minden, Mark D. ^{[4
]}

Papadantonakis, Nikolaos ^{[5
]}

Abedin, Sameem ^{[6
]}

Baines, Amanda J. ^{[7
]}

Barbash, Olena ^{[8
]}

Gorman, Shelby ^{[8
]}

Kremer, Brandon E. ^{[8
]}

Borthakur, Gautam M. ^{[9
]}

机构：

[1] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[2] Univ Miami, Sylvester Canc Ctr, Miami, FL USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Univ Hlth Network, Dept Med Oncol & Hematol, Leukemia Program, Princess Margaret Canc Ctr, Toronto, ON, Canada

[5] Taussig Canc Inst, Birmingham, AL USA

[6] Northwestern Mem Hosp, McGaw Med Ctr, Milwaukee, WI USA

[7] GlaxoSmithKline, Stevenage, Herts, England

[8] GlaxoSmithKline, Collegeville, PA USA

[9] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-130337

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2656

引用

页数：4

共 50 条

[21] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
Navada, Shyamala C.
Odchimar-Reissig, Rosalie
Reddy, E. Premkumar
Holland, James F.
Wilhelm, Francois
Silverman, Lewis R.
BLOOD, 2012, 120 (21)
[22] A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
Swaminathan, Mahesh
Kantarjian, Hagop M.
Levis, Mark
Guerra, Veronica
Borthakur, Gautam
Alvarado, Yesid
DiNardo, Courtney D.
Kadia, Tapan
Garcia-Manero, Guillermo
Ohanian, Maro
Daver, Naval
Konopleva, Marina
Pemmaraju, Naveen
Ferrajol, Alessandra
Andreeff, Michael
Jain, Nitin
Estrov, Zeev
Jabbour, Elias J.
Wierda, William G.
Pierce, Sherry
Pinsoy, Maria Rhona
Xiao, Lianchun
Ravandi, Farhad
Cortes, Jorge E.
HAEMATOLOGICA, 2021, 106 (08) : 2121 - 2130
[23] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
Daver, Naval
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Pemmaraju, Naveen
Kadia, Tapan
DiNardo, Courtney
Jain, Nitin
Borthakur, Gautum
Cortes, Jorge
Adam, Craig
Ravandi, Farhad
CANCER RESEARCH, 2014, 74 (19)
[24] Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes
Haque, Tamanna
Lopez Cadenas, Felix
Xicoy, Blanca
Alfonso, Ana
Platzbecker, Uwe
Avivi, Irit
Brunner, Andrew M.
Chromik, Joerg
Morillo, Daniel
Patel, Manish R.
Falantes, Jose F.
Leitch, Heather A.
Germing, Ulrich
Preis, Meir
Lavie, David
Lenox, Laurie
Lauring, Josh
Kalota, Anna
Brown, Regina
Mehta, Jaydeep
Pastore, Friederike
Mistry, Pankaj
Valcarcel, David
BLOOD, 2021, 138
[25] A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies
Borthakur, Gautam
Dawson, Mark A.
Stein, Eytan M.
Karadimitris, Anastasios
Huntly, Brian J. P.
Dickinson, Michael J.
Chaidos, Aristeidis
Horner, Thierry
Brennan, John
Baron, January
Kremer, Brandon E.
Dhar, Arindam
BLOOD, 2016, 128 (22)
[26] A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER plus breast cancer
Pluard, Timothy
Oh, Sun Young
Oliveira, Mafalda
Cescon, David
Tan-Chiu, Elizabeth
Wu, Yuehui
Carpenter, Chris
Cunningham, Elizabeth
Ballas, Marc
Dhar, Arindam
Sparano, Joseph
CANCER RESEARCH, 2018, 78 (04)
[27] A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER plus breast cancer
Sparano, Joseph A.
Cescon, David W.
Oliveira, Mafalda
Stover, Daniel G.
Tan-Chiu, Elizabeth
Kremer, Brandon Edward
Barbash, Olena
Wu, Yuehui
Mathew, Lijoy
Cunningham, Elizabeth Ann
Carpenter, Christopher L.
Ballas, Marc S.
Dhar, Arindam
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Soriano, Andres O.
Yang, Hui
Faderl, Stefan
Estrov, Zeev
Giles, Francis
Ravandi, Farhad
Cortes, Jorge
Wierda, William G.
Ouzounian, Souzanne
Quezada, Andres
Pierce, Sherry
Estey, Elihu H.
Issa, Jean-Pierre J.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2007, 110 (07) : 2302 - 2308
[29] Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study
Welch, John S.
Klco, Jeffery M.
Gao, Feng
Procknow, Elizabeth
Uy, Geoffery L.
Stockerl-Goldstein, Keith E.
Abboud, Camille N.
Westervelt, Peter
DiPersio, John F.
Hassan, Anjum
Cashen, Amanda F.
Vij, Ravi
AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (09) : 796 - 800
[30] Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS).
Garcia-Manero, G.
Minden, M.
Estrov, Z.
Verstovsek, S.
Newsome, W. M.
Reid, G.
Besterman, J.
Li, Z.
Pearce, L.
Martell, R.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 337S - 337S

← 1 2 3 4 5 →